// App-Quantinova.ai

e21598 : A multicenter retrospective analysis of nivolumab in advanced melanoma during the French Temporary Authorization Use.

Researchers

Presenter

  • Sandrine Monestier

Principal Investigators

  • Laurent Mortier

  • Caroline Dutriaux

  • Sophie Dalac-Rat

  • Nicolas Meyer

  • Marie Therese Leccia

  • Sandrine Mansard

  • Jean-Philippe Lacour

  • Philippe Saiag

  • Patrick Combemale

  • Bernard Guillot

  • Francois Skowron

  • Pascal Joly

  • Nathalie Beneton

  • Ewa Hainaut

  • Nabahet Ameur

  • Emilie Varey

  • Amir Khammari

  • Brigitte Dreno

Medical Centers

  • AP-HM Dermatology department, Hopital de la Timone, Universite Aix-Marseille, Marseille, France

  • Lyon University, Cancerology Institute of Lyon Civic Hospital, Cancer Research Centre of Lyon, Lyon, France, Pierre Benite, France

  • Dermatology department, CHRU de Lille, Hopital Claure Huriez, Lille, France

  • Dermatology and Pediatric dermatology department, Bordeaux hospital, Bordeaux, France, Bordeaux, France

  • Dermatology department, CHU Dijon Bourgogne, CHU Le Bocage, Dijon, France

  • Dermatology department, Institut Universitaire du Cancer de Toulouse et CHU de Toulouse, Toulouse, France

  • Universite de Grenoble, Grenoble, France

  • Dermatology department, CHU Clermont-Ferrand, CHU Estaing, Clermont Ferrand, France

  • Dermatology department, CHU Nice, Hopital Archet 2, Nice, France

  • AP-HP General & Oncology Dermatology department, Hopital Ambroise Pare, Boulogne-Billancourt, France

  • Onco-dermatology unit, Centre Leon Berard, Lyon, France

  • Dermatology department, CHU Montpellier, Hopital Saint-Eloi, Montpellier, France

  • Dermatology department, CH Valence, Valence, France

  • Dermatology department, CHU Rouen, Hopital Charles Nicolle, Rouen, France

  • Dermatology department, CH Le Mans, CH Francois Quesnay, Le Mans, France

  • Dermatology department, CHU de Poitiers, Poitiers, France

  • Medical Department, Immuno-oncology, Bristol-Myers Squibb Research, Reuil-Malmaison, France

  • Dermatology department, CHU Nantes, Universite Nantes, CIC 1413, CRCINA Inserm U1232, Nantes, France

  • CHU Nantes, Universite Nantes, CIC 1413, CRCINA Inserm U1232, Nantes, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved